Trial Profile

A Phase 1, Open-label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety, and Tolerability of BMS-986235 in Healthy Participants

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 986235 (Primary) ; Rifampicin
Indications Heart failure; Inflammation
Focus Pharmacokinetics
Sponsors Bristol-Myers Squibb

Most Recent Events

17 Mar 2022 Planned End Date changed from 11 Jun 2020 to 16 Mar 2020.
17 Mar 2022 Planned primary completion date changed from 11 Jun 2020 to 16 Mar 2020.
17 Mar 2022 Planned initiation date changed from 15 May 2020 to 9 Mar 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com